Biovica: Commercial progress despite a quarter with modest sales - Redeye

Biovica’s sales from clinical use of DiviTum tests are up 350% in Q3 compared with the first half, and the Pharma-related sales order book has expanded from SEK 8.1m to SEK 11.4m when announcing the Q3 report. Actual Q3 sales are modest at SEK 1.1m, and the pressure is to deliver a significant improvement until the end of April.

Länk till analysen i sin helhet: https://www.redeye.se/research/990467/biovica-commercial-progress-despite-a-quarter-with-modest-sales?utm_source=finwire&utm_medium=RSS